Sinopharm Group Co. Ltd. (SHTDY)
USD 13.79
(0.0%)
USD 13.79
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 28.3 Billion CNY | 8.29% |
| 2022 | 24.22 Billion CNY | 7.15% |
| 2021 | 22.6 Billion CNY | 10.08% |
| 2020 | 20.53 Billion CNY | 7.94% |
| 2019 | 19.02 Billion CNY | 22.97% |
| 2018 | 15.47 Billion CNY | 38.52% |
| 2017 | 11.17 Billion CNY | 6.82% |
| 2016 | 10.45 Billion CNY | 10.68% |
| 2015 | 9.44 Billion CNY | 11.6% |
| 2014 | 8.46 Billion CNY | 16.35% |
| 2013 | 7.27 Billion CNY | 19.7% |
| 2012 | 6.07 Billion CNY | 28.84% |
| 2011 | 4.71 Billion CNY | 37.68% |
| 2010 | 3.42 Billion CNY | 53.38% |
| 2009 | 2.23 Billion CNY | 19.94% |
| 2008 | 1.86 Billion CNY | 5.79% |
| 2007 | 1.76 Billion CNY | 16.67% |
| 2006 | 1.5 Billion CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.17 Billion CNY | 10.65% |
| 2024 Q2 | 6.24 Billion CNY | -13.01% |
| 2023 Q3 | 417.63 Billion CNY | 6658.68% |
| 2023 FY | 26.23 Billion CNY | 8.29% |
| 2023 Q1 | 6.92 Billion CNY | 101.89% |
| 2023 Q4 | 6.48 Billion CNY | -98.45% |
| 2023 Q2 | 6.17 Billion CNY | -10.71% |
| 2022 Q4 | -366.01 Billion CNY | -196.56% |
| 2022 Q1 | 6.22 Billion CNY | 7.96% |
| 2022 FY | 24.22 Billion CNY | 7.15% |
| 2022 Q2 | 5.94 Billion CNY | -4.49% |
| 2022 Q3 | 379.03 Billion CNY | 6272.61% |
| 2021 FY | 22.6 Billion CNY | 10.08% |
| 2021 Q3 | 6.73 Billion CNY | 24.16% |
| 2021 Q2 | 5.42 Billion CNY | -9.22% |
| 2021 Q4 | 5.76 Billion CNY | -14.31% |
| 2021 Q1 | 5.97 Billion CNY | -0.14% |
| 2020 Q2 | 4.91 Billion CNY | 2.7% |
| 2020 Q4 | 5.98 Billion CNY | -5.77% |
| 2020 Q3 | 6.34 Billion CNY | 29.23% |
| 2020 Q1 | 4.78 Billion CNY | -16.43% |
| 2020 FY | 20.53 Billion CNY | 7.94% |
| 2019 Q3 | 5.42 Billion CNY | 3.71% |
| 2019 FY | 19.02 Billion CNY | 22.97% |
| 2019 Q1 | 4.51 Billion CNY | -3.89% |
| 2019 Q2 | 5.23 Billion CNY | 15.74% |
| 2019 Q4 | 5.72 Billion CNY | 5.48% |
| 2018 Q2 | 3.29 Billion CNY | -13.47% |
| 2018 FY | 15.47 Billion CNY | 38.52% |
| 2018 Q1 | 3.81 Billion CNY | 0.92% |
| 2018 Q3 | 4.66 Billion CNY | 41.59% |
| 2018 Q4 | 4.7 Billion CNY | 0.72% |
| 2017 FY | 11.17 Billion CNY | 6.82% |
| 2017 Q3 | 3.77 Billion CNY | 55.19% |
| 2017 Q4 | 3.77 Billion CNY | 0.0% |
| 2017 Q1 | 2.43 Billion CNY | -10.05% |
| 2017 Q2 | 2.43 Billion CNY | 0.0% |
| 2016 Q1 | 2.64 Billion CNY | 5.76% |
| 2016 Q4 | 2.7 Billion CNY | 0.0% |
| 2016 Q3 | 2.7 Billion CNY | 37.65% |
| 2016 Q2 | 1.96 Billion CNY | -25.71% |
| 2016 FY | 10.45 Billion CNY | 10.68% |
| 2015 Q2 | 2.04 Billion CNY | -14.53% |
| 2015 Q3 | 2.5 Billion CNY | 22.45% |
| 2015 Q4 | 2.5 Billion CNY | 0.0% |
| 2015 FY | 9.44 Billion CNY | 11.6% |
| 2015 Q1 | 2.39 Billion CNY | 6.74% |
| 2014 FY | 8.46 Billion CNY | 16.35% |
| 2014 Q4 | 2.23 Billion CNY | 0.0% |
| 2014 Q3 | 2.23 Billion CNY | 14.19% |
| 2014 Q2 | 1.96 Billion CNY | 0.0% |
| 2014 Q1 | 1.96 Billion CNY | 0.03% |
| 2013 Q1 | 1.65 Billion CNY | 0.0% |
| 2013 FY | 7.27 Billion CNY | 19.7% |
| 2013 Q2 | 1.65 Billion CNY | 0.0% |
| 2013 Q4 | 1.96 Billion CNY | 0.0% |
| 2013 Q3 | 1.96 Billion CNY | 18.22% |
| 2012 FY | 6.07 Billion CNY | 28.84% |
| 2011 FY | 4.71 Billion CNY | 37.68% |
| 2010 FY | 3.42 Billion CNY | 53.38% |
| 2009 FY | 2.23 Billion CNY | 19.94% |
| 2008 FY | 1.86 Billion CNY | 5.79% |
| 2007 FY | 1.76 Billion CNY | 16.67% |
| 2006 FY | 1.5 Billion CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| China Medicine Corporation | 6.71 Million USD | -421187.078% |
| DH Enchantment Inc. | 144.83 Thousand USD | -19541360.164% |
| Exlites Holdings International, Inc. | 34.23 Thousand USD | -82675923.136% |
| Itonis, Inc. | 40.11 Thousand USD | -70555025.393% |
| One Step Vending Corp. | 26.55 Thousand USD | -106592559.687% |
| MediPal Holdings Corporation | 1.22 Billion USD | -2207.077% |
| PD-Rx Pharmaceuticals, Inc. | 6.9 Million USD | -409991.406% |
| Pharmagen, Inc. | 6038.12 USD | -468729951.738% |
| Suzuken Co., Ltd. | 993.51 Million USD | -2748.724% |